• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 16, 2016

View Archived Issues

PDUFA VI: Shift fee burden, listen to patients

Combination products. Breakthrough therapies. Sentinel. Biomarkers. And the patient voice. Those were the words buzzing Monday throughout the FDA’s public meeting on the PDUFA VI agreement it’s reached with industry and patient groups. Read More

In the clinic

Paratek Pharmaceuticals Inc., of Boston, dosed the first patient in its second pivotal phase III study of omadacycline in patients with acute bacterial skin and skin structure infections. The study will assess the efficacy and safety of once-daily oral-only omadacycline compared with twice-daily oral-only linezolid (Zyvox, Pfizer Inc.). Omadacycline is described as a new once-daily oral and intravenous, well-tolerated, broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections. Read More

Financings

Amarin Corp. plc, of Dublin, said the underwriters of its public offering of American Depositary shares (ADSs) have exercised in full their option to purchase up to 3.16 million additional ADSs, which increases the size of the offering to 24.26 million ADSs at $2.85 per ADS. The net proceeds from this offering are expected to be approximately $64.6 million. Jefferies LLC and Citigroup Global Markets Inc. are acting as joint book-running managers in the offering. Cantor Fitzgerald & Co. is acting as lead manager and H.C. Wainwright & Co. and Suntrust Robinson Humphrey are acting as co-managers in this offering. Read More

Patient deaths distract the Street from Aurinia Pharmaceuticals' promising lupus data

What should have been a big win for Aurinia Pharmaceuticals Inc.’s stock (NASDAQ:AUPH) Monday on the back of positive phase IIb data in the particularly tough lupus nephritis (LN) indication turned into a drubbing for the shares, which plunged 56 percent as investor attention focused – perhaps unfairly – on the study’s death rate. Read More

Acelrx builds case for pain drug approval with new phase III data

Acelrx Pharmaceuticals Inc. moved its sublingual sufentanil candidate ARX-04 (sufentanil sublingual tablet, 30 mcg) closer to an anticipated FDA new drug application (NDA) filing this year, announcing top-line results of a small phase III results that showed emergency room (ER) patients realizing an average 35 percent drop in pain intensity one hour after treatment. The trial bolstered safety data for inclusion in the NDA while also ruling out any cognitive impairment issues, chief medical officer and co-founder Pamela Palmer told BioWorld Today. Read More

Japan’s biopharmas hold steady in 1Q despite drug price revisions

TOKYO – Japan’s major pharmaceutical companies have, by-and-large, managed to overcome a series of reverses including drug price reductions and a slowing economy. Read More

Brexit doubts eased as U.K. commits to underwrite R&D grants

LONDON – The U.K. government has moved to end uncertainty about access to European research and development grants following the vote to leave the EU, saying it will underwrite payments on projects that continue beyond the date at which the country finally pulls out. Read More

Samsung files $2.7B IPO, eyes biosimilars to fill revenue gap from slow phone sales

HONG KONG – Samsung Group is taking its Samsung Biologics Co. Ltd. subsidiary public in Korea as it renews its commitment to develop more biosimilars. Read More

Protein induces therapeutic angiogenesis

HONG KONG – A protein that promotes angiogenesis can successfully be used to treat acute myocardial infarction (MI) in mice, offering the prospect of heart bypass without the need for surgery. Read More

Other news to note

Tivorsan Pharmaceuticals Inc., of Providence, R.I., said the FDA granted orphan drug designation to its lead candidate, human recombinant biglycan, to treat Duchenne muscular dystrophy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe